文献速递垂体与肾上腺疾病

口服避孕药对原发性醛固酮增多症筛查试验的影响:一项10年纵向研究

Effect of Oral Contraception on Screening Tests for Primary Aldosteronism: A 10-Year Longitudinal Study.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

本研究基于Raine队列女性子代,在17岁(N=484)和27岁(N=486)评估口服避孕药(OC)对醛固酮与肾素比值(ARR)筛查原发性醛固酮增多症(PA)的影响。结果显示OC使用者ARR显著升高,ARR>70 pmol/mU的比例在17岁为12.6% vs 2.1%、27岁为6.4% vs 0.4%,但血压与ARR<70者相当。结论认为OC可导致PA筛查假阳性,在更可靠标准建立前筛查期间应考虑替代避孕方式。

要点

  • OC使用者17岁时醛固酮中位数486 pmol/L,显著高于非使用者347 pmol/L(P<0.001)。
  • OC使用者ARR在17岁为31.5 vs 18.3,27岁为27.3 vs 21.1,均显著高于非使用者。
  • ARR>70 pmol/mU的比例OC使用者17岁12.6% vs 2.1%,27岁6.4% vs 0.4%,但血压与ARR<70者相当。

核心结论

  • OC可升高ARR并导致PA筛查假阳性。
  • 在针对OC使用者的更可靠PA筛查标准建立之前,筛查期间应考虑替代避孕方式。

研究设计与样本

  • 回顾性队列研究,分析Raine研究(基于人群的出生队列)女性子代在17岁(N=484)和/或27岁(N=486)时有血压测量、血样和OC使用信息的数据。

主要发现

  • OC使用者17岁时醛固酮中位数486 pmol/L vs 非使用者347 pmol/L,P<0.001。
  • OC使用者肾素浓度17岁13.4 mU/L vs 20.6 mU/L,27岁9.2 mU/L vs 11.8 mU/L,均显著低于非使用者。
  • OC使用者ARR在17岁31.5 vs 18.3,27岁27.3 vs 21.1,均显著高于非使用者。
  • ARR>70 pmol/mU(当前PA检测阈值)的比例OC使用者17岁12.6% vs 2.1%,27岁6.4% vs 0.4%,均显著高于非使用者;但该人群血压与ARR<70者相当。
  • 任何年龄的OC使用均消除了非使用者中观察到的ARR与血压之间的关系。

关键数值与推荐

  • PA筛查的当前ARR阈值为>70 pmol/mU。

临床怎么用

  • 作者认为OC可导致PA筛查假阳性,在更可靠标准建立前筛查期间应考虑替代避孕方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Primary aldosteronism (PA) and oral contraception (OC) can both cause hypertension in young women. However, the effect of OC on the screening test for PA, the aldosterone to renin ratio (ARR), is not clear. OBJECTIVE: We evaluated the impact of OC on the screening test for PA. METHODS: In this retrospective cohort study, we analyzed data from the female offspring (Gen2) of women enrolled in the Raine Study, a population-based birth cohort, who had blood pressure (BP) measurements, blood samples, and information about OC use at age 17 years (N = 484) and/or age 27 years (N = 486). RESULTS: Aldosterone concentration was significantly higher in OC users than nonusers at 17 years (median 486 pmol/L vs 347 pmol/L, P < 0.001). Renin concentration was significantly lower in OC users at both 17 years (13.4 mU/L vs 20.6 mU/L) and 27 years (9.2 mU/L vs 11.8 mU/L), hence the ARR was significantly higher in OC users compared to nonusers at both 17 years (31.5 vs 18.3) and 27 years (27.3 vs 21.1). The proportion of participants with ARR > 70 pmol/mU (current threshold for PA detection) was significantly higher in OC users at both 17 years (12.6% vs 2.1%) and 27 years (6.4% vs 0.4%); however, they had comparable BP to those with ARR < 70. OC use at any age abolished the relationship between ARR and BP that is observed in nonusers. CONCLUSION: OC can increase the ARR and cause a false positive PA screening result. Until more reliable criteria for PA screening in OC users are established, alternative contraception should be considered during screening.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Yang J, Gwini SM, Beilin LJ, et al. Effect of Oral Contraception on Screening Tests for Primary Aldosteronism: A 10-Year Longitudinal Study. J Clin Endocrinol Metab. 2023. PMID: 36633572. doi:10.1210/clinem/dgad010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。